Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Squamous Cell Carcinoma of the Lung: early-phase trial registry
2 of 3 indexed Squamous Cell Carcinoma of the Lung trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Squamous Cell Carcinoma of the Lung: 3 US clinical trials tracked, 2 recruiting.
Squamous Cell Carcinoma of the Lung is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Bicara Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition squamous-cell-carcinoma-of-the-lung
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Squamous Cell Carcinoma of the Lung lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma of the Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Squamous Cell Carcinoma of the Lung is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United
NCT07217171
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
SOTIO Biotech
NCT05120271
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Squamous Cell Carcinoma of the Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Squamous Cell Carcinoma of the Lung trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Squamous Cell Carcinoma of the Lung page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Squamous Cell Carcinoma of the Lung trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bicara Therapeutics sponsors the most Squamous Cell Carcinoma of the Lung trials on record, review their full trial history before evaluating a specific study. See Bicara Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma of the Lung condition card totals 3 registered trials; most-linked intervention CAR-GPC3 T Cells; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.